Drugs / MT-5111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04029922 | Nov 2019 → Feb 2023 | HER2 positive breast carcinoma | Molecular Templates, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-5111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04029922 ↗ |
| Modality | Protein / enzyme biologic | “MT-5111 (a recombinant fusion protein)” NCT04029922 ↗ |
| Route | Intravenous | “MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes” NCT04029922 ↗ |